Needham & Company LLC Reiterates “Hold” Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports.

Separately, Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $24.16 on Thursday. The firm has a market cap of $1.15 billion, a PE ratio of 8.05, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The business has a 50 day moving average price of $28.68 and a two-hundred day moving average price of $38.14. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals has a fifty-two week low of $22.74 and a fifty-two week high of $53.96.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. raised its holdings in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after buying an additional 1,347,775 shares during the period. Boston Trust Walden Corp grew its stake in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after purchasing an additional 439,281 shares in the last quarter. Boston Partners acquired a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $15,778,000. Wealthfront Advisers LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth about $9,268,000. Finally, Systematic Financial Management LP acquired a new position in Amphastar Pharmaceuticals in the fourth quarter worth approximately $9,147,000. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.